Growth and Development Clinical Trial
Official title:
A Double Blind, Randomized, Two-way Cross-over Study to Investigate the Uptake of Iron From Micronutrient Fortified Powder vs. From Tailored Control in Milk.
Verified date | January 2015 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | India: Institutional Review Board |
Study type | Interventional |
The present study supplements iron as part of multiple micro-nutrient supplementation to demonstrate that intake of a micronutrient fortified powder in milk helps increase the uptake of key micronutrients like iron due to unique nature of the given matrix, as compared to intake of iron alone in milk.
Status | Completed |
Enrollment | 25 |
Est. completion date | March 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 7 Years to 10 Years |
Eligibility |
Inclusion Criteria: - Demonstrates understanding of the study and willingness to participate as evidenced by participants' parents and/or legal guardian's voluntary written informed consent as well as written assent by the participant and has received a signed and dated copy of the informed consent form as well as the assent form - Participant belonging to middle socio-economic background as per modified Kuppuswamy scale - Good general and mental health with, in the opinion of the investigator or medically qualified designee - Child residing in the peri-urban areas of Bangalore city - Child with Z-scores of: a. height for age of 0 to =-3; b. BMI for age of 0 to =-3. Exclusion Criteria: - Children in Care (CiC) - Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds), any of their stated ingredients or any known food allergies like peanut allergy, gluten allergy or lactose intolerance - Participants with severe anaemia (Haemoglobin < 8g %) as determined by laboratory results - Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any medical disorder that would make the participant unlikely to fully complete the study or any condition that presents undue risk from the study product or procedures in the opinion of the investigator - Recent history (3 months) of serious infections, injuries and/ or surgeries - Children consuming iron, calcium and/or other nutritional supplements and/ or health food drinks on a regular basis (more than 3 times a week) in last 6 months prior to screening visit - Use of any prescription medications within 15 days prior to screening and throughout the entire duration of the study - Recent history (within the last 1 year) of alcohol or other substance abuse. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fractional iron absorption | Iron absorption from each of the treatment regimens will be measured 14 days after the first treatment is administered (i.e. on study day 15). This will be expressed as percentage(%) iron absorbed. Blood samples will be collected from each participant on the 15th day and all isotopic analysis will be carried on a negative thermal ionization mass spectrometer (Triton) equipped with a multicollector system for simultaneous ion beam detection. The % iron absorbed will be log transformed prior to analysis, and analysed using an analysis of covariance (ANCOVA). The ANCOVA will include factors for sequence, participant within sequence (random effect), treatment group, study period and gender, with baseline levels of 57 Fe and 58 Fe isotopes as a covariate. | 15 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05370989 -
Technology-Based Parent School Program
|
N/A | |
Recruiting |
NCT05138276 -
Effect of Autologous Cord Blood Mononuclear Cells for Digestive System in Preterm Neonates
|
Early Phase 1 | |
Completed |
NCT02345187 -
fMRI Study to Investigate Hemodynamic Changes in Brain Resulting From Supplementation of Bacopa Monnieri Extract and Multiple Micronutrient Supplementation.
|
N/A | |
Completed |
NCT04624347 -
NEOVIDEO : Impact of Monitoring Motor Activity by Video Analysis on the Sleep of Very Preterm Infants
|
N/A | |
Completed |
NCT03155269 -
To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers in Indian Healthy Premenopausal Women (25- 45 Years) After 6 Months of Intervention
|
N/A | |
Completed |
NCT02437721 -
Suitability of an Infant Formula With L-5-Methyltetrahydrofolate for the Particular Nutritional Use in Infants
|
N/A | |
Completed |
NCT02428699 -
Study Comparing Blood Levels of Fatty Acids After Consuming Two Forms of Cod Liver Oil
|
N/A | |
Completed |
NCT02428127 -
Efficacy of a Carbohydrate Drink on Speed, Agility and Power in School Going Children
|
N/A | |
Completed |
NCT03395015 -
Efficacy of Maxillo-facial Treatment on Cleft Lip and Palate Patients Faces: Aesthetic Considerations
|
N/A | |
Withdrawn |
NCT02551627 -
A Study to Investigate the Impact of a Multiple Micronutrient (MMN) Beverage Powder on Vaccine Response in School Children
|
N/A | |
Completed |
NCT02542865 -
A Study to Investigate the Impact of Fortified Malt Based on Immunity Outcomes in School Children
|
N/A | |
Completed |
NCT02805192 -
Validation of a Smart Phone App to Non-invasively Measure the Size of Children
|
N/A | |
Active, not recruiting |
NCT03099837 -
Tongji Maternal and Child Health Cohort
|
||
Completed |
NCT03519503 -
Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety
|
||
Completed |
NCT02338609 -
Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301
|
Phase 4 | |
Recruiting |
NCT05868408 -
Effect of Partially Hydrolyzed, Whey-based Infant Formulas on Growth and Tolerability in Healthy Term Infants
|
N/A |